Dr. Alexandra Santana Sorensen, head of development of compounds, said: ‘We are very pleased with the progress in developing a sustained release formulation of EV-077, which now allows us to develop pharmacodynamic and safety profile of repeated administration of doses growing, which brings us one step closer to creating a proof of concept in a population of patients. ‘Evolva Holding AG (SIX: EVE) today announced it has launched a first ascending phase multiple-dose clinical trial with an oral formulation of extended-release EV-077.
An earlier version of the first single ascending dose study in man with an oral solution of EV-077 said it is a powerful, fast-acting, reversible platelet aggregation. After the formulation of development work to optimize the pharmacokinetic profile has led to four different oral sustained-release formulations being evaluated in a crossover study involving 12 to four lanes in healthy volunteers and conducted in Germany. The study showed that all formulations were well tolerated, and identified a candidate that could lead to maximize exposure.
EV-077 (EV-name-2TBS 077-3201) is a new chemical entity, with a different mode of action of existing drugs in development for indications of kidney disease and cardiovascular diseases, especially kidney disease and proteinuria anti-platelet indications .